

1 **Title**

2 Criteria to Achieve Safe Antimicrobial Intravenous-to-Oral Switch in Hospitalised Adult Populations:

3 A Systematic Rapid Review

4 **Author Information**

5 Eleanor J Harvey¹, Monsey McLeod², Caroline De Brún³, Diane Ashiru-Oredope^{1,4*}

6 **Affiliations**

7 ¹Healthcare-Associated Infection (HCAI), Fungal, Antimicrobial Resistance (AMR), Antimicrobial Use

8 (AMU) & Sepsis Division, United Kingdom Health Security Agency (UKHSA), London, UK

9 ²Antimicrobial Prescribing and Medicines Optimisation, NHS England & NHS Improvement, London,

10 UK

11 ³ Knowledge and Library Services, United Kingdom Health Security Agency (UKHSA), London, UK

12

⁴ School of Pharmacy, University of Nottingham, Nottingham, UK

13 **Corresponding Author**

14 *Diane Ashiru-Oredope: diane.ashiru-oredope@ukhsa.gov.uk, +44 2083 276689

15 Abstract

16 **Introduction:** Antimicrobial stewardship and patient safety strategies include early intravenous-to-
17 oral switch (IVOS) for antimicrobials.

18 **Aim:** This rapid review aimed to assess and collate IVOS criteria from the literature to achieve safe
19 and effective antimicrobial IVOS in the hospital inpatient adult population.

20 **Method:** The rapid review follows the PRISMA statement and is registered with PROSPERO.
21 Systematic literature searches were conducted. Articles of adult populations published between
22 2017-2021 were included. IVOS criteria from UK hospital IVOS policies were categorised to inform
23 the framework synthesis of the literature criteria.

24 **Results:** IVOS criteria from 45/164 (27%) UK IVOS policies were categorised into a 5-section
25 framework: 1-Timing of IV antimicrobial review, 2-Clinical signs and symptoms, 3-Infection markers,
26 4-Enteral route, and 5-Infection exclusions. The literature search identified 477 papers, of which 16
27 were included. The most common timing for review was 48-72 hours from initiation of intravenous
28 antimicrobial (n=5, 30%). Nine studies (56%) stated clinical signs and symptoms must be improving.
29 Temperature was the most frequently mentioned infection marker (n=14, 88%). Endocarditis had
30 the highest mention as an infection exclusion (n=12, 75%). Overall, 33 IVOS criteria were identified
31 to go forward into the Delphi process.

32 **Conclusion:** Through the rapid review, 33 IVOS criteria were collated and presented within 5 distinct
33 and comprehensive sections. The literature highlighted the possibility of reviewing IVOS before 48-
34 72 hours, and of presenting HR, BP and RR as a combination early warning score criterion. The
35 criteria identified can serve as a starting point of IVOS criteria review for any institution globally, as
36 no country or region limits were applied. Further research is required to achieve consensus on IVOS
37 criteria from healthcare professionals that manage patients with infections.

38 What is already known on this topic

39 Antimicrobial intravenous-to-oral switch has benefits such as decreased risk of catheter-related
40 infections, reduced equipment costs and increased patient mobility and comfort. Acute hospitals
41 often develop and implement individualised IVOS policies with varying levels of evidence base.

42 What this study adds

43 This study provides evidence-based IVOS criteria to standardise practice in hospital settings.

44 How this study might affect research, practice or policy

45 IVOS criteria can be taken forward through a consensus process with healthcare professionals
46 providing the care for hospitalised adult patients and making the decisions regarding infection
47 management. In the acute hospital setting, IVOS criteria can be operationalised to promote best
48 practice. The criteria can also be considered as part of organisation-wide audits and quality/policy
49 incentives.

50 1 Introduction

51 Antimicrobial resistance (AMR) is a public health threat,¹ and tackling this threat requires joint
52 efforts at local, national and global levels across all care settings.² In the acute hospital care setting,
53 antibiotic consumption is known to promote resistant and multidrug-resistant bacteria leading to
54 healthcare-associated infections.³ Antibiotic prescribing in England continued to rise in acute
55 hospitals between 2016 and 2020, with specialist hospitals accounting for the highest increase of
56 31.2%.⁴

57 Antimicrobial stewardship (AMS) is defined as a set of strategies to promote the responsible use of
58 antimicrobials⁵ for the purpose of protecting public health.⁶ Across secondary care, the COVID-19
59 pandemic had a negative impact on AMS activities, but evidence suggests the pandemic also
60 encouraged collaboration between infection specialists and non-specialists to strengthen activities
61 going forward.⁷ Antimicrobial intravenous-to-oral switch (IVOS) has been classified as a “low-hanging
62 fruit” AMS activity; in other words, an attainable AMS strategy despite constrained limitations.⁸
63 The literature outlines numerous benefits for IVOS; including decreased risk of catheter-related
64 infections, reduced equipment costs and increased patient mobility and comfort.^{9, 10} Additionally,
65 decreased medical equipment usage has the potential to reduce hospital’s carbon footprint.¹¹ In
66 clinically stable patients, studies report that a timely IVOS is safe and of equal efficacy to the full
67 course of IV therapy,¹² with no negative reports on patient outcome.¹² In the United Kingdom (UK),
68 the national Start Smart – Then Focus AMS Toolkit recommends IVOS as an important outcome
69 following review of prescribed antimicrobial within 48-72 hours.

70 Acute hospitals have developed and implemented their own individualised local IVOS policies and
71 there is currently no standardised national criteria recommended for IVOS in the UK. The evidence-
72 base behind the criteria included in the individualised policies is largely unknown. Additionally, they
73 include a variety of criteria themes and nuances in criterion wording. The standardisation of clinical
74 guidance, whether protocols, checklists or other, has led to enhanced patient safety and outcomes
75 and driven improved quality of care.¹³⁻¹⁵

76 This rapid review aims to evaluate the evidence-base for IVOS criteria and collate criteria into
77 common themes. This review will subsequently inform a Delphi consensus-gathering process, led by
78 the UK Health Security Agency (UKHSA), to establish standardised, evidence-based, national
79 antimicrobial IVOS criteria. The UK has previously never had nation-wide IVOS criteria available for
80 use by hospitals, this review will form the basis for included IVOS criteria.

81 2 Method

82 2.1 Protocol and registration

83 This review was informed by the World Health Organisation¹⁶ and Cochrane¹⁷ rapid review protocols,
84 and follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020
85 item checklist (**Supplementary Table S1**) and guidance.^{18,19} The review protocol is registered with
86 PROSPERO [registration number CRD42022320343].²⁰

87 2.2 Eligibility criteria

88 Articles were included in the review if they were written in English, pertained to an adult (18 years of
89 age or over) population, were clinical trials, review articles, studies or point prevalence studies with
90 a publication date between January 2017 and December 2021, related to the AMS strategy IVOS and
91 with specified IVOS criteria.

92 Studies were excluded if they were case reports and non-studies e.g., conference abstracts,
93 editorials, letters, notes, or related to one particular antimicrobial or specific infection (to exclude
94 non-generalisable criteria).

95 2.3 Information sources

96 Literature search terms were devised alongside an experienced UKHSA Knowledge and Evidence
97 Specialist (CD). Systematic searches were conducted in OVID Embase and OVID Medline databases.
98 For the initial searches, no start date limit was set, and databases were searched up to 15 December
99 2021.

100 2.4 Search strategy

101 The defined research question was: What are the criteria necessary to achieve a safe and effective
102 antimicrobial intravenous-to-oral switch in the hospital inpatient adult population?

103 See **Table 1** for database search strategies.

104 2.5 Selection process

105 Article duplicates were removed on EndNote. One researcher (EH) screened all titles and abstracts
106 for articles relevant to the research question. From this initial screening, Akhloufi *et al.*'s paper
107 published in 2017 was identified as including an IVOS literature review,²¹ thus 2017 onwards became
108 an inclusion criterion to capture evidence published since the most recently identified review. One
109 researcher (EH) screened full articles to ascertain focus of article and identify IVOS criteria. A second
110 researcher (DAO) reviewed the focus themes for accuracy.

111 A second assessment of a random 20% sample of articles dated between the years 2017 and 2021
112 was conducted by a third researcher (MM). Discrepancies were resolved between two reviewers
113 (EH, MM) with a third reviewed (DAO) as arbiter.

114 2.6 Data collection process

115 A data extraction Excel spreadsheet was designed with the following column headings: Authors, Year
116 of publication, Title, Journal, Edition, Pages, Month, Article type, DOI, Keywords, Abstract, URL link,
117 Database, Platform, Language, Continent research conducted in, Country/area, Sample size,
118 Population, Focus, Specifics, Healthcare professional mention, Key findings, Exclude/Include, Reason,
119 Additional comments.

120 The Focus heading options included AMS (focus on AMS strategies such as IVOS), Antimicrobial
121 (focus on an individual or class of antimicrobial(s)) or Infection (focus on specific infection). Studies
122 with an AMS focus would further be classified under the Specifics column as General (non-IVOS AMS
123 strategy) or IV Switch (IVOS AMS strategy). The studies in the IV Switch column were further
124 evaluated to ascertain if they included IVOS switch criteria.

125 2.7 Data items

126 The primary outcome sought from the literature was safety of antimicrobial IVOS, defined by
127 measurable IV switch criteria for adults (to include review time, clinical signs and symptoms,
128 infection markers, enteral route, infection exclusions).
129 Additional outcomes were reduced healthcare associated infections, reduced catheter-related
130 infections, reduced hospital length of stay, reduced costs (e.g., drug equipment), reduced staff
131 workload, reduced IV administration errors, increased patient comfort and mobility, improved AMS
132 practice.

133 2.8 Study risk of bias assessment

134 The included studies were not assessed for internal validity with a risk of bias tool. This differs to the
135 protocol registered on PROSPERO. This decision was agreed by all co-authors and the reasons are: 1)
136 as a rapid review the risk of bias can be omitted,²² and 2) risk of bias tools become more relevant for
137 studies assessing effectiveness of interventions, whereas this review aimed to identify IVOS criteria
138 to subsequently inform a Delphi consensus-gathering process.

139 2.9 Synthesis methods

140 There was heterogeneity of study designs and outcome measures. This was expected and was not
141 investigated as outside scope of the rapid review. A framework synthesis on included studies was
142 completed.

143 2.9.1 Development of framework

144 The framework was derived based on an analysis of IVOS criteria obtained from a sample of UK
145 acute hospital IVOS policies sought through stratified sampling. The target number of IVOS policies
146 was 41 (25%), to include policies from English Trusts and Scottish Health Boards and Northern Ireland
147 and Wales all-country policies. Hospitals from England were selected from an 'All England Trusts and
148 Trust Types' UKHSA datasheet by hospital type (acute – small, acute – medium, acute – large, acute
149 – multi-service, acute – specialist, acute – teaching) and region (East of England, London, Midlands,
150 North East and Yorkshire, North West, South East, South West) to ensure representative sampling.

151 English IVOS policies were obtained through internet search or MicroGuide application access. IVOS
152 policies from Scotland's Health Boards were obtained through internet search, and from Northern
153 Ireland and Wales through internet search and email correspondence. An Excel spreadsheet was
154 designed to collate criteria under headings to inform framework sections.

155 2.10 Certainty of evidence

156 All included studies were peer-reviewed articles, enhancing the certainty of the evidence. Studies
157 were not formally graded. High evidence rating [H] was assigned to high quality evidence such as
158 clinical trials and reviews, and medium evidence rating [M] was assigned to lower quality studies
159 such as prospective studies and point prevalence studies.

160 3 Results

161 3.1 Framework synthesis

162 Forty-two acute hospitals (28%, n=148) from England were selected for review of their IVOS policies,
163 two Health Boards (14%, n=14) from Scotland and the All-Wales policy from Wales. No IVOS policy
164 from Northern Ireland was identified at the time of the study period. Overall, 45 (27%, n=164) acute
165 hospital IVOS policies from three UK nations were included for review. IVOS criteria were collated on
166 an Excel spreadsheet under the following 5 framework sections and headings: Review IV within
167 (hours) (Section 1: Timing of IV antimicrobial review); Clinical signs and symptoms (Section 2: Clinical
168 signs and symptoms); Temperature, Heart rate, Blood pressure, Respiratory rate, White cell count,
169 C-reactive protein (Section 3: Infection markers); Gut function, Drug interactions with oral therapy,
170 Allergy to oral therapy (Section 4: Enteral route); and Infection exclusions (Section 5: Infection
171 exclusions) (**Supplementary Table S2**).

172 3.2 Study selection

173 Four hundred seventy-seven papers were identified from the literature search. Fifty-nine were non-
174 studies (e.g., letters, notes, conference abstracts) and therefore excluded. Akhloufi *et al.*'s IVOS
175 review in 2017²¹ led to the timeframe of included papers to be between 2017 and 2021, excluding a

176 further 308 papers. The remaining 110 articles were screened for relevance to the research question
177 by title and abstract. Seventy papers were excluded due to a focus other than AMS. Forty papers
178 were found to be eligible for inclusion and screened by full article. A further 24 papers were
179 excluded as they contained no IVOS criteria or pertained to the paediatric population (n=1). Sixteen
180 papers with IVOS criteria were included for review. See **Figure 1** for PRISMA flowchart.
181 The primary outcome of safety of antimicrobial IVOS was identified in eight of the included papers
182 (50%),^{12, 21, 23-28} with remaining papers focusing on outcomes classed as additional for the purposes
183 of this study. All papers included measurable IVOS criteria.

184 3.3 Study characteristics

185 Most published papers were from 2021 (n=4) and 2018 (n=4). The Netherlands had published the
186 most peer-reviewed articles (n=6), followed by two each from the United Kingdom and Australia,
187 and one each from Canada, India, Malaysia, Switzerland, Thailand and Vietnam. Eight papers
188 presented IVOS criteria for use in clinical practice in table format, two in flowchart format and one as
189 text. The remaining five articles did not state how IVOS criteria were presented. The majority (n=11)
190 had a Switch approach, 4 were unknown and one had a Continue approach (**Table 2**). Switch
191 approach referred to criteria being expressed in terms of 'if patient meets x criteria, consider switch
192 from intravenous to oral therapy', instead of the Continue approach of 'if patient does not meet x
193 criteria, consider continuing intravenous therapy'.

194 3.4 Results of individual studies

195 **Table 2** includes a summary of results of individual studies, including identified IVOS criteria.

196 3.5 Results of syntheses

197 Eight studies (50%) specified criteria for all 5 sections of the defined framework. Criteria with
198 highest, or over 50%, appearance in the literature, informed by evidence rating was collated.
199 Overall, 33 criteria were identified to go forward into the Delphi process (**Table 3**).

200 3.5.1 Timing of intravenous antimicrobial review

201 Eleven of the 16 included studies (69%) contained criteria pertaining to the timing of IV antimicrobial
202 review.

203 Five of the studies (30%) stated that a review should take place either *within* (n=3), *at* (n=1) or *after*
204 (n=1) the 48–72-hour window from initiation of IV antimicrobial. A clinical trial [H]⁹ and a further two
205 studies [M]^{26, 28} defined early switch as IVOS taking place within the 48-72 hours.

206 Three studies (19%) stated that a review must occur *within* (n=1) or *after* (n=2) 48 hours from
207 initiation of IV antimicrobial. A systematic review [H] investigated early IVOS as being within 48
208 hours.²⁹ Three studies (19%) [M] recommended IVOS review to occur after 24 hours.^{27, 30, 31}

209 3.5.2 Clinical signs and symptoms

210 Ten of the 16 studies (63%) included clinical signs and symptoms as a criterion for early IVOS. Nine
211 studies (56%) stated that clinical signs and symptoms must be improving; one of these studies was a
212 (non-systematic) review article [H]. A variance in criterion wording was captured by one study that
213 stated that clinical signs and symptoms must be resolved or improving for safe IVOS.²¹

214 3.5.3 Infection markers

215 The infection markers identified in the literature were temperature,^{9, 12, 21, 23, 25-28, 30-35} heart rate,^{9, 32-34}
216 blood pressure,^{12, 21, 23, 26-28, 31-35} respiratory rate,^{9, 12, 32, 33} white cell count^{9, 12, 24, 27, 28, 30, 32-34} or
217 absolute neutrophil count^{24, 30} and C-reactive protein.^{32, 33}

218 3.5.3.1 Temperature

219 Temperature was the most frequently mentioned infection marker, appearing in 14 of the 16 studies
220 (88%). The most common criterion variance was that temperature must be between the 36-38°C
221 range, appearing in 6 studies (38%). Of these 6 studies, three stated that 36-38°C must have been
222 sustained for the past 24 hours – one of these studies was a clinical trial [H],¹² and one stated for the
223 past 24-48 hours, also a clinical trial [H].⁹ Six studies (38%) [M] did not state a temperature range,
224 but instead suggested that it must be less than 38°C,^{27, 30, 31, 33, 34} or less than 37.6°C.²⁵ Two studies

225 (13%) did not specify a temperature at all, but instead commented on the need for patient's fever to
226 be resolved or improving,³⁵ or patient to be afebrile.²⁸

227 *3.5.3.2 Heart rate*

228 Four of the 16 studies (25%) included heart rate (HR) as an infection marker for safe IVOS. Two of
229 them (12.5%) stated HR must be below 90 beats/minute – the clinical trial [H] provided no
230 timeframe,⁹ whilst the study [M] stated HR must have been sustained for the past 12 hours.³²

231 *3.5.3.3 Blood pressure*

232 Eleven of the 16 studies (69%) included blood pressure (BP) as an infection marker for early IVOS.
233 The most common wording for the criterion was BP needed to be stable (n=3, 19%),^{28, 31, 32} and BP
234 needed to be stable without inotropics or fluid resuscitation (n=3, 19%).^{21, 26, 27}

235 *3.5.3.4 Respiratory rate*

236 Four of the 16 studies (25%) included respiratory rate (RR) as an infection marker for IVOS. Three
237 studies (19%) stated RR must be below 20 breaths/minute; two of them had no associated
238 timeframe,^{9, 33} of which one was a clinical trial [H],⁹ and the third, a study [M], stated that the
239 specified RR must have been sustained for the past 24 hours.³²

240 *3.5.3.5 White cell count*

241 Nine of the 16 studies (56%) included white cell count (WCC) or absolute neutrophil count within
242 criteria for early IVOS. The preferred wording was divided between WCC must be normalising (n=3,
243 19%)^{9, 27, 34} and WCC must be within $4-12 \times 10^9/L$ (n=3, 19%).^{12, 28, 33} Each of these criterion wordings
244 appeared in clinical trials [H].^{9, 12}

245 *3.5.3.6 C-reactive protein*

246 C-reactive protein (CRP) was the least included infection marker, appearing in only 2 of the 16
247 studies (13%). Both studies [M] stated that CRP must be normalising for a safe IVOS.^{32, 33}

248 3.5.4 Enteral route

249 Fourteen of the 16 included studies (88%) had criteria that related to the enteral route. The most
250 common criteria in the literature was that there must be no malabsorption, appearing in 11 of the
251 16 studies (69%), of which one was a clinical trial [H]⁹ and one a review [H].³⁵
252 Nine studies (56%) stated that the gut must be functioning and 5 studies (31%) stated the patient
253 must not be vomiting.

254 3.5.5 Infection exclusions

255 This section included both general information (e.g., infections requiring prolonged IV therapy, deep-
256 seated infections) as well as specifically mentioned infections. The infections with highest counts in
257 the literature were endocarditis (n=12, 75%) including in two clinical trials [H]^{9, 12} and one review³⁵
258 and meningitis (n=8, 50%). Infections with lowest appearance in the literature included mediastinitis
259 (n=4, 25%) and bone and joint infections (n=2, 12.5%).

260 4 Discussion

261 Early IVOS has numerous advantages compared to continuing intravenous therapy in patients that
262 may be eligible for oral administration. The risk of cannula-related infections and thrombophlebitis
263 would reduce, as would the costs of equipment and staff time. Patient comfort and mobility would
264 be promoted, and the absence of intravenous antimicrobial infusions or injections could result in
265 earlier patient discharge from hospital.³⁶ Analysis of individualised hospital IVOS policies showcased
266 the variety of IVOS criteria in clinical use. The standardisation of healthcare practice benefits patient
267 safety and outcomes, however it must be evidence-based.³⁷ Through this rapid review, the literature
268 was systematically searched and 33 IVOS criteria were identified as part of a 5-section framework.

269 4.1 Criteria sections

270 4.1.1 Timing of intravenous antimicrobial review

271 The most common timing stated in the literature for IVOS review from initiation of antimicrobial
272 intravenous therapy was 48-72 hours, specifically within the 48–72-hour window. Prior guidance

273 outlines the need to review patients' clinical diagnosis and ongoing need for antibiotics at 48-72
274 hours.^{38, 39} In the UK national Start Smart – Then Focus AMS Toolkit,³⁸ switching antibiotics from
275 intravenous to oral is one of five recommended choices, alongside stopping antibiotics, changing to
276 a narrower or broader spectrum antibiotic, continuing antibiotic treatment stating time of next
277 review or considering Outpatient Parenteral Antibiotic Therapy. Studies have since questioned
278 whether an earlier review, such as review within 48 hours of intravenous initiation, is warranted.^{29, 40}
279 Van den Broek *et al.* commented that theoretical reasons for an early switch (even within 24 hours)
280 exist; for example, if patient has an intact gastrointestinal tract and the oral antibiotic option has
281 adequate bioavailability (generally data obtained from studies carried out in healthy and/or critically
282 ill patients). However, improved knowledge on antimicrobial bioavailability in the acute stage of
283 infectious illness, when the patient may be febrile and drug pharmacokinetics more unfamiliar,
284 would further strengthen the case for earlier IVOS.²⁹

285 4.1.2 Clinical signs and symptoms

286 Signs as objective manifestations of infectious disease, and symptoms as subjective manifestations,⁴¹
287 underline the importance of noting improvement, or deterioration, in both the observed response to
288 infection and its management as well as the self-reported accounts of the patient. This rapid review
289 showcases evidence to suggest that the improvement of a patient's signs and symptoms is an
290 important criterion to include for safe IVOS.^{21, 24-27}

291 4.1.3 Infection markers

292 Temperature was the predominant infection marker criterion across all studies, with higher evidence
293 for stating a temperature range compared to stating that temperature must be below a certain
294 figure. Infection can elicit thermoregulation in the host, increasing body temperature
295 (fever/hyperthermia) or decreasing it (hypothermia) as in the case of sepsis,⁴² thus corroborating the
296 importance of including a temperature range in IVOS criteria.
297 Despite temperature being a vital marker of infection, normothermia, categorised as 36.1-38°C, has
298 been associated with infection and higher patient mortality than hyperthermia.⁴³ Normothermia

299 therefore does not exclude the need for antibiotics; and if antibiotics are given, normothermia
300 would not necessarily mean that a switch from intravenous to oral therapy should be made. Other
301 infection markers, to include physiological and inflammatory parameters,⁴³ must be considered to
302 ensure any IVOS decision is safe.

303 The National Early Warning Score (NEWS) developed by the UK Royal College of Physicians is a
304 recognised clinical assessment tool for use in acute hospital and ambulance settings. It was first
305 published in 2012 with a second version, NEWS2, released in 2017. The tool ‘improves the detection
306 and response to clinical deterioration in adult patients and is a key element of patient safety and
307 improving patient outcomes’.^{13, 44} NEWS2 aggregates individual scores from the following
308 physiological parameters: respiration rate, oxygen saturation, systolic blood pressure, pulse rate,
309 level of consciousness or new confusion, and temperature. Certain parameters overlap with the
310 IVOS criteria found in the literature, notably temperature, but also respiration/respiratory rate and
311 blood pressure. The marker named heart rate in this rapid review is specified as pulse rate in
312 NEWS2.

313 For each marker of HR, BP and RR, the literature showcased a variety of nuances in criteria wording.
314 Some criteria, but not all, specify marker values with or without a particular timeframe for which the
315 specified infection marker must be sustained for; e.g., HR below 90 beats/min for the past 12 hours.
316 The benefit of the NEWS2 score is that ranges, not merely single values, are used to assess clinical
317 deterioration. Additionally, it is a tool endorsed for use in patients with acute infection or at risk of
318 infection and widely implemented across UK NHS hospitals.¹³ Presenting separate criteria for HR, BP
319 and RR is one way to achieve safe IVOS,^{12, 21, 23, 26-28} however presenting them combined into a
320 NEWS2 scoring criterion would offer an alternative evidence-based way to achieve safe IVOS.

321 Other countries have also adopted Early Warning Scores (EWS) to identify patients at risk of
322 deterioration, especially from infection, thus IVOS criteria in other countries could consider EWS as a
323 criterion. In Canada, for example, the Hamilton Early Warning Score of similar prognostic accuracy to

324 NEWS2 is used.⁴⁵ In the United States of America, a variety of tools exist with the NEWS tool
325 considered most accurate to identify patients at high risk of mortality.⁴⁶

326 4.1.4 Enteral route

327 This section of the framework is concerned with maximising enteral antibiotic absorption from the
328 gastrointestinal tract (GIT), and hence maximising antibiotic bioavailability and therapeutic action.

329 Antibiotic administration via the intravenous route achieves 100% bioavailability.³⁶ Some antibiotics
330 are known to have good oral bioavailability, for example clindamycin, doxycycline, linezolid and
331 metronidazole have over 90% oral bioavailability.^{36, 47}

332 The literature outlines numerous criteria to ensure a switch to oral administration, or indeed to
333 enteral administration to include use of enteral tubes, achieves as close to 100% bioavailability as
334 practicable. The criteria centre on patient characteristics, predominantly in relation to their GIT
335 function e.g., no malabsorption present, but also in relation to their level of alertness e.g., patient is
336 not unconscious. The latter resonates with one of the physiological scores included in the NEWS2
337 (level of consciousness or new confusion scoring),¹³ further promoting inclusion of EWS as a
338 combination criterion for safe IVOS.

339 The literature includes no mention of antibiotic pharmacological properties such as antibiotic
340 bioavailability, nor the need to review drug interactions between oral antibiotic options and any
341 other medication the patient may be taking or to check for allergies. It is worth noting that these
342 criteria do appear in the sample of acute hospital IVOS policies used to inform the framework
343 analysis (**Supplementary Table S2**).

344 4.1.5 Infection exclusions

345 Over the years, randomised controlled trials have been undertaken comparing treatment arms of
346 prolonged intravenous antibiotic courses and shorter courses. The research has demonstrated equal
347 outcomes between treatment arms for infections such as community-acquired pneumonia and
348 neutropenic fever.⁴⁸ These results have enabled change in clinical practice and advancement in AMS.

349 However, not all infections have the evidence to make them eligible for early IVOS. This section of
350 the framework provides a caveat around certain infections when making early IVOS decisions.
351 Endocarditis was the infection exclusion with highest appearance in the literature. The POET trial
352 enrolled patients with left-sided endocarditis and compared full course intravenous therapy versus
353 oral switch after a minimum of 10 days intravenous therapy. IVOS was found to be noninferior in
354 terms of treatment failure at one year compared to full intravenous therapy.⁴⁹ However, the timing
355 of IVOS (after at least 10 days of intravenous therapy) was much later than the timing for IVOS
356 proposed in the included literature for this rapid review. Considering the current available evidence,
357 endocarditis may remain as an infection exclusion within IVOS criteria.
358 Bone and joint infections appeared only twice in the literature, in papers published in 2018³⁴ and
359 2019.³⁰ Around that time, the OVIVA trial investigated early IVOS for bone and joint infections and
360 concluded that oral antibiotic treatment was noninferior to intravenous treatment. Trial IVOS
361 decisions were led by specialist teams,⁵⁰ so it remains to be said that in the standardisation process
362 of IVOS criteria, which also serves to equip non-specialist teams, professional judgment regarding
363 when to refer patients for specialist input remains important in IVOS decision-making.

364 4.2 Strengths and limitations

365 A strength of this study includes a systematic literature search being undertaken to capture papers
366 relevant to IVOS AMS strategy. Papers were not limited by country or region, thus the criteria
367 identified can serve as a starting point for any institution globally. Two researchers (EH, DAO) were
368 involved in reviewing themes and included papers, with a separate researcher (MM) undertaking a
369 second assessment of a random sample of papers.

370 A limitation is that non-English papers were excluded, potentially discounting research on IVOS
371 criteria conducted in non-English speaking nations. During the study period, the authors were not
372 aware of a published validated rapid review reporting protocol.⁵¹ However, the WHO and Cochrane
373 approaches to rapid reviews were taken into consideration and the authors followed through the
374 PRISMA reporting guidelines.

375 5 Conclusion

376 The benefits of early IVOS include reduced risk of healthcare-associated and catheter-related
377 infections, reduced costs, staff workload and hospital length of stay, and increased patient mobility
378 and comfort. Individual hospital policies contain variable IVOS criteria with an unknown evidence-
379 base. This rapid review has identified and collated 33 evidence-based IVOS criteria from the
380 literature and presented them within 5 distinct and comprehensive sections.

381 Further research is required to achieve a national consensus on IVOS criteria from healthcare
382 professionals providing the care for hospitalised adult patients and making the decisions regarding
383 infection management. In the acute hospital setting, operationalisation of IVOS criteria as a tool to
384 promote best practice needs to be explored and must take into consideration the roles and
385 strengths that a multidisciplinary team brings to AMS.

386 **6 Author contributions**

387 Conceptualisation: DAO, EH. Methodology: EH undertook framework analysis, literature review and
388 drafted paper, CD contributed to literature searches, MM undertook the random second assessment
389 of articles, DAO validated aspects of methodology and supervised the review. All authors reviewed
390 and approved final version.

391 **7 Funding**

392 This research was funded by the UK Health Security Agency. The views expressed in this publication
393 are those of the author(s) and not necessarily those of the UK Health Security Agency.

394 **8 Declarations**

395 None to declare.

396 **9 Ethics approval**

397 This study does not involve human participants.

398 **10 Data availability statement**

399 All data relevant to the study are included in the article or uploaded as supplemental information.

400 11 References

- 401 1. Murray CJL, Ikuta KS, Sharara F, *et al.* Global burden of bacterial antimicrobial resistance in
402 2019: a systematic analysis. *Lancet*, 2022. 399(10325): p. 629-655.
- 403 2. O'Neill J. Tackling drug-resistant infectious globally: final report and recommendations. 2016,
404 [Date accessed: August 2022]: [https://apo.org.au/sites/default/files/resource-files/2016-](https://apo.org.au/sites/default/files/resource-files/2016-05/apo-nid63983.pdf)
405 [05/apo-nid63983.pdf](https://apo.org.au/sites/default/files/resource-files/2016-05/apo-nid63983.pdf).
- 406 3. European Centre for Disease Prevention and Control. Summary of the latest data on
407 antibiotic consumption in the European Union. 2017, [Date accessed: August 2022]:
408 [https://www.ecdc.europa.eu/sites/default/files/documents/Final_2017_EAAD_ESAC-](https://www.ecdc.europa.eu/sites/default/files/documents/Final_2017_EAAD_ESAC-Net_Summary-edited%20-%20FINALwith%20erratum.pdf)
409 [Net_Summary-edited%20-%20FINALwith%20erratum.pdf](https://www.ecdc.europa.eu/sites/default/files/documents/Final_2017_EAAD_ESAC-Net_Summary-edited%20-%20FINALwith%20erratum.pdf).
- 410 4. UK Health Security Agency. English surveillance programme for antimicrobial utilisation and
411 resistance (ESPAUR) report. 2021, [Date accessed: August 2022]:
412 [https://www.gov.uk/government/publications/english-surveillance-programme-](https://www.gov.uk/government/publications/english-surveillance-programme-antimicrobial-utilisation-and-resistance-espaur-report)
413 [antimicrobial-utilisation-and-resistance-espaur-report](https://www.gov.uk/government/publications/english-surveillance-programme-antimicrobial-utilisation-and-resistance-espaur-report).
- 414 5. Dyar OJ, Huttner B, Schouten J, *et al.* What is antimicrobial stewardship? *Clin Microbiol*
415 *Infect*, 2017. 23(11): p. 793-798.
- 416 6. Viasus D, Vecino-Moreno M, De La Hoz JM, *et al.* Antibiotic stewardship in community-
417 acquired pneumonia. *Expert Rev Anti Infect Ther*, 2017. 15(4): p. 351-359.
- 418 7. Ashiru-Oredope D, Kerr F, Hughes S, *et al.* Assessing the impact of COVID-19 on antimicrobial
419 stewardship activities/programs in the United Kingdom. *Antibiotics*, 2021. 10(2): p. 110.
- 420 8. Goff DA, Bauer KA, Reed EE, *et al.* Is the “low-hanging fruit” worth picking for antimicrobial
421 stewardship programs? *Clin Infect Dis*, 2012. 55(4): p. 587-592.
- 422 9. Nguyen AD, Mai-Phan TA, Tran MH, *et al.* The effect of early switching from intravenous to
423 oral antibiotic therapy: a randomized controlled trial. *J Pharm Pharmacogn Res*, 2021. 9(5):
424 p. 695-703.
- 425 10. Schuts EC, Hulscher M, Mouton JW, *et al.* Current evidence on hospital antimicrobial
426 stewardship objectives: a systematic review and meta-analysis. *Lancet Infect Dis*, 2016.
427 16(7): p. 847-856.
- 428 11. Tennison I, Roschnik S, Ashby B, *et al.* Health care's response to climate change: a carbon
429 footprint assessment of the NHS in England. *The Lancet Planetary Health*, 2021. 5(2): p. e84-
430 e92.
- 431 12. Wongkamhla T, Khan-Asa B, Tongchai S, *et al.* Infectious Disease Team Review Using
432 Antibiotic Switch and Discharge Criteria Shortens the Duration of Intravenous Antibiotic: A
433 Single-Center Cluster-Randomized Controlled Trial in Thailand. *Open Forum Infect Dis*, 2020.
434 7(12): p. ofaa539.
- 435 13. Royal College of Physicians. National Early Warning Score (NEWS) 2: Standardising the
436 assessment of acute-illness severity in the NHS. 2017, [Date accessed: August 2022]:
437 <https://www.rcplondon.ac.uk/projects/outputs/national-early-warning-score-news-2>.
- 438 14. ACOG. Clinical guidelines and standardization of practice to improve outcomes. Committee
439 opinion no. 629. *Obstet Gynecol*, 2015. 125(4): p. 1027-1029.
- 440 15. Stone J. Defining standardization and personalized care, Medical GPS, Editor. 2020, [Date
441 accessed: August 2022]: [https://blog.medicalgps.com/defining-standardization-and-](https://blog.medicalgps.com/defining-standardization-and-personalized-care/)
442 [personalized-care/](https://blog.medicalgps.com/defining-standardization-and-personalized-care/).
- 443 16. Tricco AC, Langlois E, Straus SE, *et al.*, Rapid reviews to strengthen health policy and
444 systems: a practical guide. 2017: World Health Organization.
- 445 17. Garrity C, Gartlehner G, Nussbaumer-Streit B, *et al.* Cochrane Rapid Reviews Methods
446 Group offers evidence-informed guidance to conduct rapid reviews. *Journal of clinical*
447 *epidemiology*, 2021. 130: p. 13-22.
- 448 18. Page MJ, McKenzie JE, Bossuyt PM, *et al.* The PRISMA 2020 statement: an updated guideline
449 for reporting systematic reviews. *Syst Rev*, 2021. 10(1): p. 1-11.

- 450 19. Page MJ, Moher D, Bossuyt PM, *et al.* PRISMA 2020 explanation and elaboration: updated
451 guidance and exemplars for reporting systematic reviews. *BMJ*, 2021. 372.
- 452 20. Harvey E and Ashiru-Oredope D. Criteria to achieve safe and effective antimicrobial
453 intravenous to oral switch in hospitalised adults: a rapid review. *PROSPERO*, 2022.
454 CRD42022320343.
- 455 21. Akhloufi H, Hulscher M, Melles DC, *et al.* Development of operationalized intravenous to oral
456 antibiotic switch criteria. *J Antimicrob Chemother*, 2017. 72(2): p. 543-546.
- 457 22. Haby MM, Chapman E, Clark R, *et al.* What are the best methodologies for rapid reviews of
458 the research evidence for evidence-informed decision making in health policy and practice: a
459 rapid review. *Health Syst Policy Res*, 2016. 14(1): p. 1-12.
- 460 23. Akhloufi, H, M Hulscher, CP Van Der Hoeven, *et al.* A clinical decision support system
461 algorithm for intravenous to oral antibiotic switch therapy: Validity, clinical relevance and
462 usefulness in a three-step evaluation study. *Journal of Antimicrobial Chemotherapy*, 2018.
463 73(8): p. 2201-2206.
- 464 24. Berrevoets, MAH, JHLW Pot, AE Houterman, *et al.* An electronic trigger tool to optimise
465 intravenous to oral antibiotic switch: A controlled, interrupted time series study.
466 *Antimicrobial Resistance and Infection Control*, 2017. 6(1) (no pagination).
- 467 25. Kan T, Kwan D, Chan T, *et al.* Implementation of a Clinical Decision Support Tool to Improve
468 Antibiotic IV-to-Oral Conversion Rates at a Community Academic Hospital. *Can J Hosp
469 Pharm*, 2019. 72(6): p. 455-461.
- 470 26. Khumra S, Mahony AA, Bergen PJ, *et al.* Evaluation of intravenous to oral antimicrobial
471 switch at a hospital with a tightly regulated antimicrobial stewardship program. *Br J Clin
472 Pharmacol*, 2021. 87(8): p. 3354-3358.
- 473 27. Tejaswini YS, Challa SR, Nalla KS, *et al.* Practice of intravenous to oral conversion of
474 antibiotics and its influence on length of stay at a tertiary care hospital: A prospective study.
475 *J Clin Diagn Res*, 2018. 12(3): p. FC01-FC04.
- 476 28. Van Den Bosch CMA, Hulscher MEJL, Akkermans RP, *et al.* Appropriate antibiotic use reduces
477 length of hospital stay. *J Antimicrob Chemother*, 2017. 72(3): p. 923-932.
- 478 29. van den Broek AK, Prins JM, Visser CE, *et al.* Systematic review: the bioavailability of orally
479 administered antibiotics during the initial phase of a systemic infection in non-ICU patients.
480 *BMC Infect Dis*, 2021. 21(1) (no pagination).
- 481 30. Gurtler N, Erba A, Giehl C, *et al.* Appropriateness of antimicrobial prescribing in a Swiss
482 tertiary care hospital: a repeated point prevalence survey. *Swiss Med Wkly*, 2019. 149: p.
483 w20135.
- 484 31. Mouwen AMA, Dijkstra JA, Jong E, *et al.* Early switching of antibiotic therapy from
485 intravenous to oral using a combination of education, pocket-sized cards and switch advice:
486 A practical intervention resulting in reduced length of hospital stay. *Int J Antimicrob Agents*,
487 2020. 55(1): p. 105769.
- 488 32. Dutey-Magni PF, Gill MJ, McNulty D, *et al.* Feasibility study of hospital antimicrobial
489 stewardship analytics using electronic health records. *JAC Antimicrob Resist*, 2021. 3(1) (no
490 pagination).
- 491 33. Powell N, McGraw-Allen K, Menzies A, *et al.* Identifying antibiotic stewardship interventions
492 to meet the NHS England CQUIN: An evaluation of antibiotic prescribing against published
493 evidence-based antibiotic audit tools. *J R Coll Physicians Lond*, 2018. 18(4): p. 276-281.
- 494 34. Sze WT and Kong MC. Impact of printed antimicrobial stewardship recommendations on
495 early intravenous to oral antibiotics switch practice in district hospitals. *Pharm Pract*, 2018.
496 16(2): p. 855.
- 497 35. McCarthy K and Avent M. Oral or intravenous antibiotics? *Aust Prescr*, 2020. 43(2): p. 45-48.
- 498 36. Cyriac JM and James E. Switch over from intravenous to oral therapy: a concise overview. *J
499 Pharmacol Pharmacother*, 2014. 5(2): p. 83-87.

- 500 37. World Medical Association. WMA resolution on standardiation in medical practice and
501 patient safety, in *Current Policies,, Policy*, Editor. 2022, [Date accessed: August 2022]:
502 [https://www.wma.net/policies-post/wma-resolution-on-standardisation-in-medical-](https://www.wma.net/policies-post/wma-resolution-on-standardisation-in-medical-practice-and-patient-safety/)
503 [practice-and-patient-safety/](https://www.wma.net/policies-post/wma-resolution-on-standardisation-in-medical-practice-and-patient-safety/).
- 504 38. Public Health England. Start Smart – Then Focus: Antimicrobial stewardship toolkit for
505 English hospitals. 2015, [Date accessed: August 2022]:
506 [https://www.gov.uk/government/publications/antimicrobial-stewardship-start-smart-then-](https://www.gov.uk/government/publications/antimicrobial-stewardship-start-smart-then-focus)
507 [focus](https://www.gov.uk/government/publications/antimicrobial-stewardship-start-smart-then-focus).
- 508 39. Nathwani D, Lawson W, Dryden M, *et al*. Implementing criteria-based early switch/early
509 discharge programmes: A European perspective. *Clin Microbiol Infect*, 2015. 21(Supplement
510 2): p. S47-S55.
- 511 40. Cunha CB. Antibiotic stewardship program perspective: Oral antibiotic therapy for common
512 infectious diseases. *Med Clin*, 2018. 102(5): p. 947-954.
- 513 41. King LS. Signs and symptoms. *JAMA*, 1968. 206(5): p. 1063-1065.
- 514 42. Schieber AMP and Ayres JS. Thermoregulation as a disease tolerance defense strategy.
515 *Pathog Dis*, 2016. 74(9).
- 516 43. Schuttevaer R, Brink A, Alsmas J, *et al*. The association of body temperature with antibiotic
517 therapy and mortality in patients attending the emergency department with suspected
518 infection. *Eur J Emerg Med*, 2021. 28(6): p. 440.
- 519 44. NHS England. National Early Warning Score (NEWS). 2022, [Date accessed: August 2022]:
520 <https://www.england.nhs.uk/ourwork/clinical-policy/sepsis/nationalearlywarningscore/>.
- 521 45. Fernando SM, Fox-Robichaud AE, Rochweg B, *et al*. Prognostic accuracy of the Hamilton
522 Early Warning Score (HEWS) and the National Early Warning Score 2 (NEWS2) among
523 hospitalized patients assessed by a rapid response team. *Critical Care*, 2019. 23(1): p. 1-8.
- 524 46. Liu VX, Lu Y, Carey KA, *et al*. Comparison of early warning scoring systems for hospitalized
525 patients with and without infection at risk for in-hospital mortality and transfer to the
526 intensive care unit. *JAMA network open*, 2020. 3(5): p. e205191-e205191.
- 527 47. Quinn NJ, Sebaaly JC, Patel BA, *et al*. Effectiveness of oral antibiotics for definitive therapy of
528 non-Staphylococcal Gram-positive bacterial bloodstream infections. *Therapeutic Advances in*
529 *Infectious Disease*, 2019. 6: p. 2049936119863013.
- 530 48. Wald-Dickler N and Spellberg B. Short-course antibiotic therapy—replacing constantine units
531 with “shorter is better”. 2019, Oxford University Press US. p. 1476-1479.
- 532 49. Iversen K, Ihlemann N, Gill SU, *et al*. Partial oral versus intravenous antibiotic treatment of
533 endocarditis. *N Engl J Med*, 2019. 380(5): p. 415-424.
- 534 50. Li H-K, Rombach I, Zambellas R, *et al*. Oral versus intravenous antibiotics for bone and joint
535 infection. *N Engl J Med*, 2019. 380(5): p. 425-436.
- 536 51. Stevens A, Garritty C, Hersi M, *et al*. Developing PRISMA-RR, a reporting guideline for rapid
537 reviews of primary studies (Protocol). *equator network*, 2018.

538

Table 1. OVID Embase and OVID Medline search strategies

OVID Embase

1. exp *antiinfective agent/
2. exp *anti-infective therapy/
3. exp *antimicrobial therapy/
4. antimicrobial stewardship.tw.
5. 1 or 2 or 3 or 4
6. ((IV or intravenous or early or antibiotic or oral) adj3 switch*).tw.
7. IVOS*.tw.
8. 6 or 7
9. 5 and 8
- 10 limit 9 to (human and english language)
- .

OVID Medline

1. Anti-Infective Agents/
2. Antimicrobial Stewardship/
3. 1 or 2
4. ((IV or intravenous or early or antibiotic or oral) adj3 switch*).tw.
5. IVOS*.tw.
6. 4 or 5
7. 3 and 6

Figure 1. PRISMA flowchart of the literature search and rapid review




Table 2. Summary of results of individual studies

Article	Outcome sought	Evidence rating	Layout	Approach	Timing of IV antimicrobial review (h)	Clinical signs and symptoms	Infection markers	Enteral route	Infection exclusions
Akhloufi H et al., 2017 ¹	Safety of IVOS	[M]	Table	Switch	After 48-72	Resolved or improving	Temperature 36-38 °C, BP stable without inotropics or fluid resuscitation	Functioning gut; no malabsorption, short bowel syndrome, severe gastroparesis, ileus, continuous nasogastric suction, vomiting; patient is cooperative	Infections requiring high concentration; severe sepsis, necrotising fasciitis, bacteraemia, endovascular infection, CNS infection
Akhloufi et al., 2018 ²	Safety of IVOS	[M]	Table	Switch	-	-	Temperature 36-38 °C (past 24h), BP >90 mmHg	-	-
Berrevoets et al., 2017 ³	Safety of IVOS	[M]	Table	Switch	At 48-72	Improving	ANC >0.5 x10 ⁹ /L	Functioning gut; no malabsorption, short bowel syndrome, vomiting, nausea; patient tolerates oral route	Infections requiring prolonged IV therapy; necrotising fasciitis, bacteraemia, endocarditis, meningitis, neutropenia, abscess, mediastinitis, infection of foreign bodies, cystic fibrosis, empyema

Dutey-Magni PF et al., 2021 ⁴	Improved AMS practice	[M]	Text	Switch	-	Improving	Temperature 36-38 °C (past 24h), HR <90 beats/min (past 12h), BP stable (past 24h), RR <20 breaths/min (past 24h), WCC 4-12 x10 ⁹ /L or normalising, CRP normalising	Functioning gut; no malabsorption; patient tolerates oral/enteral feeding	Deep-seated, high-risk infections and infections requiring high concentration; necrotising soft tissue, bacteraemia, endocarditis, meningitis, neutropenia, abscess, mediastinitis, foreign body infection, cystic fibrosis, bronchiectasis, osteomyelitis, septic arthritis, pneumonia
Gurtler N et al., 2019 ⁵	Improved AMS practice	[M]	Unknown	Switch	After 24	Improving	Temperature <38 °C, ANC >0.5 x10 ⁹ /L	Functioning gut	Endocarditis, abscess, bone/joint infection
Kan T et al., 2019 ⁶	Safety of IVOS Improved AMS practice	[M]	Table	Switch	After 48	Improving	Temperature <37.6 °C (past 24h)	Functioning gut; not nil by mouth; patient tolerates oral route	Bacteraemia, endocarditis, meningitis, neutropenia
Khumra S et al., 2021 ⁷	Safety of IVOS Improved AMS practice	[M]	Flowchart	Continue	Within 48-72	Improving	Temperature 36-38 °C, BP stable without inotropics or fluid resuscitation	No malabsorption, short bowel syndrome, ileus, vomiting, severe diarrhoea, not nil by mouth; patient tolerates	Deep-seated infections; necrotising soft tissue, bacteraemia, endocarditis, meningitis, neutropenia, abscess, implant of prosthesis

								oral/enteral feeding	infection, empyema, osteomyelitis, septic arthritis
McCarthy K & Avent M, 2020 ⁸	Improved AMS practice	[H]	Table	Switch	-	Improving	Fever resolved or improving, no unexplained haemodynamic instability	No malabsorption; patient tolerates oral route	Infections requiring high concentration and prolonged IV therapy; endocarditis, meningitis
Mouwen AMA et al., 2020 ⁹	Improved AMS practice Reduced hospital length of stay	[M]	Flowchart	Switch	After 24	Improving	Temperature <38 °C (past 24h), BP stable (past 24h)	No malabsorption, vomiting, diarrhoea; patient tolerates oral route	-
Nguyen AD et al., 2021 ¹⁰	Effectiveness of IVOS Reduced hospital length of stay Reduced costs	[H]	Unknown	Unknown	Within 48-72	-	Temperature 36-38 °C (past 24-48h), HR <90 beats/min, RR <20 breaths/min, WCC normalising	No malabsorption, ileus, severe diarrhoea, gastrectomy, dysphagia; patient tolerates oral route, not unconscious	Septic shock, cellulitis, bacteraemia, endocarditis, meningitis, immunodeficiency, prosthetic material infection, osteomyelitis, pneumonia, cirrhosis
Powell N et al., 2018 ¹¹	Improved AMS practice	[M]	Table	Switch	-	-	Temperature <38 °C (past 24h), HR <100 beats/min (past 12h), BP >100	Functioning gut; no malabsorption; patient tolerates oral route	Deep-seated infections; bacteraemia, endocarditis, meningitis,

							mmHg, RR <20 breaths/min, WCC 4-12 x10 ⁹ /L, CRP normalising		neutropenia, abscess, mediastinitis, prosthetic device or foreign body infection, cystic fibrosis, bronchiectasis, empyema, osteomyelitis, septic arthritis, pneumonia
Sze WT & Kong MC, 2018 ¹²	Improved AMS practice Reduced hospital length of stay Reduced costs	[M]	Unknown	Unknown	After 48	Improving	Temperature <38 °C (past 24h), HR <100 beats/min, BP >90 mmHg, WCC normalising	Functioning gut; no malabsorption, vomiting, severe diarrhoea, swallowing disorder, active bleeding, not nil by mouth; patient tolerates oral route, not unconscious	Infections requiring prolonged IV therapy; sepsis, bacteraemia, endocarditis, meningitis, immunodeficiency, abscess, cystic fibrosis, empyema, bone/joint infection, orbital cellulitis, endophthalmitis, melioidosis
Tejaswini YS et al., 2018 ¹³	Safety of IVOS Improved AMS practice Reduced hospital length of stay	[M]	Unknown	Unknown	After 24	Improving	Temperature <38 °C (past 24h), BP stable without inotropics or fluid resuscitation, WCC normalising	No malabsorption, active bleeding; patient tolerates oral/enteral feeding	Infections requiring prolonged IV therapy; sepsis, bacteraemia, endocarditis, CNS infection, immunodeficiency, osteomyelitis, septic arthritis, fungemia, endophthalmitis, orbital cellulitis

	Reduced costs								
van den Bosch CMA et al., 2017 ¹⁴	Safety of IVOS Reduced hospital length of stay Reduced costs	[M]	Table	Switch	Within 48-72	-	Afebrile, BP stable, WCC 4-12 x10 ⁹ /L	Functioning gut; no malabsorption; patient tolerates oral route	Soft tissue infections, bacteraemia, endocarditis, meningitis, neutropenia, abscess, mediastinitis, foreign body infection, cystic fibrosis, empyema, osteomyelitis, arthritis, Legionella pneumonia
van den Broek AK et al., 2021 ¹⁵	Improved AMS practice	[H]	Unknown	Unknown	Within 48	-	-	-	-
Wong kamhla T et al., 2020 ¹⁶	Safety of IVOS Reduced hospital length of stay	[H]	Table	Switch	-	-	Temperature 36-38 °C (past 24h), BP >100 mmHg, RR <22 breaths/min, WCC 4-12 x10 ⁹ /L	Functioning gut; patient tolerates oral route	Sepsis, endocarditis, CNS infection, neutropenia

Table 2 References

1. Akhloufi H, Hulscher M, Melles DC, *et al.* Development of operationalized intravenous to oral antibiotic switch criteria. *J Antimicrob Chemother*, 2017. 72(2): p. 543-546.
2. Akhloufi, H, M Hulscher, CP Van Der Hoeven, *et al.* A clinical decision support system algorithm for intravenous to oral antibiotic switch therapy: Validity, clinical relevance and usefulness in a three-step evaluation study. *Journal of Antimicrobial Chemotherapy*, 2018. 73(8): p. 2201-2206.
3. Berrevoets, MAH, JHLW Pot, AE Houterman, *et al.* An electronic trigger tool to optimise intravenous to oral antibiotic switch: A controlled, interrupted time series study. *Antimicrobial Resistance and Infection Control*, 2017. 6(1) (no pagination).
4. Dutey-Magni PF, Gill MJ, McNulty D, *et al.* Feasibility study of hospital antimicrobial stewardship analytics using electronic health records. *JAC Antimicrob Resist*, 2021. 3(1) (no pagination).
5. Gurtler N, Erba A, Giehl C, *et al.* Appropriateness of antimicrobial prescribing in a Swiss tertiary care hospital: a repeated point prevalence survey. *Swiss Med Wkly*, 2019. 149: p. w20135.
6. Kan T, Kwan D, Chan T, *et al.* Implementation of a Clinical Decision Support Tool to Improve Antibiotic IV-to-Oral Conversion Rates at a Community Academic Hospital. *Can J Hosp Pharm*, 2019. 72(6): p. 455-461.
7. Khumra S, Mahony AA, Bergen PJ, *et al.* Evaluation of intravenous to oral antimicrobial switch at a hospital with a tightly regulated antimicrobial stewardship program. *Br J Clin Pharmacol*, 2021. 87(8): p. 3354-3358.
8. McCarthy K and Avent M. Oral or intravenous antibiotics? *Aust Prescr*, 2020. 43(2): p. 45-48.
9. Mouwen AMA, Dijkstra JA, Jong E, *et al.* Early switching of antibiotic therapy from intravenous to oral using a combination of education, pocket-sized cards and switch advice: A practical intervention resulting in reduced length of hospital stay. *Int J Antimicrob Agents*, 2020. 55(1): p. 105769.
10. Nguyen AD, Mai-Phan TA, Tran MH, *et al.* The effect of early switching from intravenous to oral antibiotic therapy: a randomized controlled trial. *J Pharm Pharmacogn Res*, 2021. 9(5): p. 695-703.
11. Powell N, McGraw-Allen K, Menzies A, *et al.* Identifying antibiotic stewardship interventions to meet the NHS England CQUIN: An evaluation of antibiotic prescribing against published evidence-based antibiotic audit tools. *J R Coll Physicians Lond*, 2018. 18(4): p. 276-281.
12. Sze WT and Kong MC. Impact of printed antimicrobial stewardship recommendations on early intravenous to oral antibiotics switch practice in district hospitals. *Pharm Pract*, 2018. 16(2): p. 855.
13. Tejaswini YS, Challa SR, Nalla KS, *et al.* Practice of intravenous to oral conversion of antibiotics and its influence on length of stay at a tertiary care hospital: A prospective study. *J Clin Diagn Res*, 2018. 12(3): p. FC01-FC04.
14. Van Den Bosch CMA, Hulscher MEJL, Akkermans RP, *et al.* Appropriate antibiotic use reduces length of hospital stay. *J Antimicrob Chemother*, 2017. 72(3): p. 923-932.
15. van den Broek AK, Prins JM, Visser CE, *et al.* Systematic review: the bioavailability of orally administered antibiotics during the initial phase of a systemic infection in non-ICU patients. *BMC Infect Dis*, 2021. 21(1) (no pagination).
16. Wongkamhla T, Khan-Asa B, Tongyai S, *et al.* Infectious Disease Team Review Using Antibiotic Switch and Discharge Criteria Shortens the Duration of Intravenous Antibiotic: A Single-Center Cluster-Randomized Controlled Trial in Thailand. *Open Forum Infect Dis*, 2020. 7(12): p. ofaa539.

Table 3. Criteria from rapid review (n=33) to go forward into Delphi process

Criteria	Number of papers n, (%)	Evidence rating
1. Timing of IV antimicrobial review		
a. Review antimicrobial within 48 hours	1 (6)	[H]
b. Review antimicrobial within 48-72 hours	3 (19)	[M] x2, [H]
2. Clinical signs and symptoms		
a. Clinical signs and symptoms should be improving	9 (56)	[M] x8, [H]
3. Infection markers		
a. Temperature should be between 36-38°C	2 (13)	[M] x2
b. Temperature should be between 36-38 °C past 24 hours	3 (19)	[M] x2, [H]
c. Heart rate should be below 90 beats per minute	1 (6)	[H]
d. Heart rate should be below 90 beats per minute for past 12 hours	1 (6)	[M]
e. Blood pressure should be stable	1 (6)	[M]
f. Blood pressure stable for past 24 hours	2 (13)	[M] x2
g. Respiratory rate should be below 20 breaths per minute	2 (13)	[M], [H]
h. Respiratory rate should be below 20 breaths per minute for past 24 hours	1 (6)	[M]
i. White cell count should be normalising	3 (19)	[M] x2, [H]
j. White cell count should be between 4 and 12 x10 ⁹ /L	3 (19)	[M] x2, [H]
k. White cell count should be between 4 and 12 x10 ⁹ /L or normalising	1 (6)	[M]
l. C-reactive protein should be normalising	2 (13)	[M] x2
4. Enteral route		
a. Gastrointestinal tract must be functional	9 (57)	[M] x8, H
b. Patient can tolerate/ swallow oral option	9 (57)	[M] x6, [H]x3
c. No evidence of malabsorption	11 (69)	[M] x9, [H] x2
d. No vomiting	5 (31)	[M] x5
5. Infection exclusions		
a. Deep-seated infections	3 (19)	[M] x3
b. Infections requiring high tissue concentration	3 (19)	[M] x2, [H]
c. Infections requiring prolonged IV therapy	4 (25)	[M] x3, [H]

d. Critical infection with high risk of mortality	1 (6)	[M]
e. Endocarditis	12 (75)	[M] x9, [H] x3
f. Meningitis	9 (56)	[M] x7, [H] x2
g. Bacteraemia, including <i>Staph. aureus</i>	9 (56)	[M] x9
h. Immunocompromised	3 (19)	
i. Abscess	7 (44)	[M] x7
j. Severe or necrotising soft tissue infections	5 (31)	[M] x5
k. Infections of foreign bodies	6 (38)	[M] x5, [H]
l. Osteomyelitis	6 (38)	[M] x5, [H]
m. Septic arthritis	5 (31)	[M] x5
n. Empyema	5 (31)	[M] x5